GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
77.78
+0.93 (1.21%)
At close: Mar 13, 2026, 4:00 PM EDT
78.00
+0.22 (0.28%)
After-hours: Mar 13, 2026, 7:56 PM EDT
GeneDx Holdings Revenue
In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth. GeneDx Holdings had revenue of $120.99M in the quarter ending December 31, 2025, with 26.50% growth.
Revenue (ttm)
$427.54M
Revenue Growth
+39.97%
P/S Ratio
5.33
Revenue / Employee
$328,876
Employees
1,300
Market Cap
2.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| Twist Bioscience | 391.56M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
WGS News
- 1 day ago - Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note? - Benzinga
- 2 days ago - GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing - Business Wire
- 3 days ago - GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C - Business Wire
- 4 days ago - GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership - Business Wire
- 16 days ago - HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 16 days ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 17 days ago - These Analysts Slash Their Forecasts On GeneDx After Q4 Results - Benzinga